Prevention of postpartum episodes in women with bipolar disorder

Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, USA.
Biological Psychiatry (Impact Factor: 10.26). 11/2004; 56(8):592-6. DOI: 10.1016/j.biopsych.2004.07.022
Source: PubMed


The aim of this study was to evaluate the efficacy of divalproex (VLP) to prevent episode recurrence in postpartum women with bipolar disorder.
The design was a single-blind, nonrandomized clinical trial. Subjects were enrolled during pregnancy and chose either VLP plus symptom monitoring or monitoring without medication for immediate postpartum management. Mania and depression symptoms were assessed weekly for 20 weeks by an independent evaluator.
Data were available for 26 women. There were no significant differences between groups in the proportions of women who developed postpartum hypomania/mania, depression, or mixed states. The time to development of episodes also did not vary between groups. Women who were treated with VLP tended to have lower levels of hypomanic/manic symptoms.
Divalproex was not significantly more effective than monitoring without drug for the prevention of postpartum episodes of bipolar disorder. The most prudent pharmacologic plan is to use the drug(s) to which the individual woman has responded and prepare a plan for rapid augmentation if a breakthrough episode occurs.

1 Read
  • Source
    • "The effects of the mood stabilizer divalproex in preventing postpartum relapse were evaluated in an open clinical trial including 26 US women with a DSM-IV diagnosis of bipolar disorder (Wisner et al. 2004 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Postpartum psychosis is a serious disorder that can cause negative consequences for the mother, infant, and entire family. While reports of this condition date back for centuries, little is known about what interventions are most effective for this population. The purpose of this systematic review was to examine the research evidence on interventions for the prevention and treatment of postpartum psychosis. Studies were searched using CINAHL, EMBASE, MEDLINE, PsycINFO, and PubMed databases. All primary research studies published in English since 1970 that explored interventions for the prevention or treatment of postpartum psychosis were included. The search resulted in 26 studies on interventions for postpartum psychosis, with 10 focusing on prevention and 17 focusing on treatment. Studies on the prevention of postpartum psychosis have examined the effects of mood stabilizers, antipsychotics, and hormone therapy, while those examining treatment have included electroconvulsive therapy, mood stabilizers, antipsychotics, hormones, and the beta blocker propranolol. Only preliminary evidence suggests which interventions may be effective strategies to prevent (e.g., lithium) and treat (e.g., electroconvulsive therapy) postpartum psychosis. Due to methodological limitations in the studies reviewed, extensive evidence-based recommendations for the prevention and treatment of postpartum psychosis cannot be made. The known risk factors and negative consequences of postpartum psychosis point to the importance of preventative and acute treatment measures. Well-designed prospective studies are needed to determine the efficacy of prevention and treatment interventions for women who experience postpartum psychosis.
    Archives of Women s Mental Health 12/2010; 14(2):89-98. DOI:10.1007/s00737-010-0199-6 · 2.16 Impact Factor
  • Source
    • "O efeito profilático do lítio e/ou da carbamazepina em mulheres bipolares no puerpério foi observado e replicado em vários estudos (Stewart et al.,1991; Austin, 1992; Cohen et al., 1995; Viguera et al., 2000). Wisner et al. (2004) compararam a eficácia do divalproato na recorrência do TB. Não houve diferenças entre o grupo com divalproato e o de acompanhamento, entretanto, haveria uma tendência de diminuição da intensidade dos sintomas no grupo com medicação. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract
    Revista de Psiquiatria Clínica 01/2006; 33(2). DOI:10.1590/S0101-60832006000200008 · 0.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In 2005, the Canadian Network for Mood and Anxiety Treatments (CANMAT) published guidelines for the management of bipolar disorder. This update reviews new evidence since the previous publication and incorporates recommendations based on the most current evidence for treatment of various phases of bipolar disorder. It is designed to be used in conjunction with the 2005 CANMAT Guidelines. The recommendations for the management of acute mania remain mostly unchanged. Lithium, valproate and several atypical antipsychotics continue to be recommended as first-line treatments for acute mania. For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option. Lithium and lamotrigine monotherapy, olanzapine plus selective serotonin reuptake inhibitors (SSRI), and lithium or divalproex plus SSRI/bupropion continue to remain the other first-line options. First-line options in the maintenance treatment of bipolar disorder continue to be lithium, lamotrigine, valproate and olanzapine. There is recent evidence to support the combination of olanzapine and fluoxetine as a second-line maintenance therapy for bipolar depression. New data also support quetiapine monotherapy as a second-line option for the management of acute bipolar II depression. The importance of comorbid psychiatric and medical conditions cannot be understated, and this update provides an expanded look at the prevalence, impact and management of comorbid conditions in patients with bipolar disorder.
    Bipolar Disorders 01/2007; 8(6):721-39. DOI:10.1111/j.1399-5618.2006.00432.x · 4.97 Impact Factor
Show more